

Journal Pre-proof



Fetal Growth Velocity Standards from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project

Eric O. Ohuma, PhD, José Villar, MD, Yuan Feng, PhD, Luo Xiao, PhD, Laurent Salomon, MD, Fernando C. Barros, MD, Leila Cheikh Ismail, PhD, William Stones, MD, Yasmin Jaffer, MD, Manuela Oberto, MD, J Alison Noble, PhD, Michael Gravett, MD, Wu Qingqing, MD, Cesar G. Victora, MD, Ann Lambert, PhD, Paola Di Nicola, MD, Manorama Purwar, MD, Zulfiqar A. Bhutta, PhD, Stephen H. Kennedy, MD, Aris T. Papageorghiou, for the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st Project)

PII: S0002-9378(20)30826-7

DOI: <https://doi.org/10.1016/j.ajog.2020.07.054>

Reference: YMOB 13398

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 22 May 2020

Revised Date: 23 July 2020

Accepted Date: 29 July 2020

Please cite this article as: Ohuma EO, Villar J, Feng Y, Xiao L, Salomon L, Barros FC, Ismail LC, Stones W, Jaffer Y, Oberto M, Noble JA, Gravett M, Qingqing W, Victora CG, Lambert A, Di Nicola P, Purwar M, Bhutta ZA, Kennedy SH, Papageorghiou AT, for the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st Project), Fetal Growth Velocity Standards from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project, *American Journal of Obstetrics and Gynecology* (2020), doi: <https://doi.org/10.1016/j.ajog.2020.07.054>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that,

during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc.

Fetal Growth and Development of the INTERGROWTH-21st Project

Eric O OHUMA PhD^{1,2*}, José Villar MD^{3,4}, YUAN Feng PhD⁵, LUO Xiao PhD⁵, Laurent SALOMON MD⁶, Fernando C BARROS MD⁷, Leila CHEIKH ISMAIL PhD⁸, William STONES MD⁹, Yasmin JAFFER MD¹⁰, Manuela OBERTO MD¹¹, J Alison NOBLE PhD¹², Michael GRAVETT MD¹³, WU Qingqing MD¹⁴, Cesar G VICTORA MD¹⁵, Ann LAMBERT PhD³, Paola DI NICOLA MD¹⁶, Manorama PURWAR MD¹⁷, Zulfiqar A BHUTTA PhD¹⁸, Stephen H KENNEDY MD^{3,4}, Aris T PAPAGEORGHIU^{3,4}, for the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st Project)

¹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ, UK

²Maternal, Adolescent, Reproductive & Child Health (MARCH) Centre, London School of Hygiene & Tropical Medicine (LSHTM), London, UK

³Nuffield Department of Women's & Reproductive Health, University of Oxford, UK

⁴Oxford Maternal & Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK

⁵Department of Statistics, North Carolina State University, Raleigh, NC 27695, USA

⁶Department of Obstetrics and Fetal Medicine, Hôpital Necker Enfants Malades, Université Paris Descartes, Paris, France

⁷Programa de Pós-Graduação em Saúde e Comportamento, Universidade Católica de Pelotas, Pelotas, Brazil

⁸Clinical Nutrition and Dietetics Department, University of Sharjah, Sharjah, United Arab Emirates

⁹Faculty of Health Sciences, Aga Khan University, Nairobi, Kenya

¹⁰Department of Family & Community Health, Ministry of Health, Muscat, Sultanate of Oman

¹¹S.C. Ostetricia 2U, Città della Salute e della Scienza di Torino, Italy

¹²Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford, UK

¹³Departments of Obstetrics & Gynecology and of Public Health, University of Washington, Seattle 98195 WA USA

¹⁴Department of Ultrasound, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

¹⁵Programa de Pós-Graduação em Epidemiologia, Universidade Federal de Pelotas, Pelotas, Brazil

¹⁶Dipartimento di Scienze Pediatriche e dell' Adolescenza, Terapia Intensiva Neonatale Ospedale TINO, Torino

¹⁷Nagpur INTERGROWTH-21st Research Centre, Ketkar Hospital, Nagpur, India

¹⁸Center for Global Child Health, Hospital for Sick Children, Toronto, Canada

This project was supported by a generous grant from the Bill & Melinda Gates Foundation (Grant no. 49038). The funder played no role in the study design, analysis or paper preparation.

The authors report no conflicts of interest.

Corresponding author*

Eric Ohuma, BSc (Hons), MSc, D.Phil, CStat

Senior Medical Statistician

Centre for Tropical Medicine and Global Health

Nuffield Department of Medicine

The Peter Medawar Building, University of Oxford,

South Parks Road, Oxford, OX1 3SY, UK

Email: eric.ohuma@ndm.ox.ac.uk

Word count 4893

52 Fetal Growth Velocity Standards from the Fetal Growth Longitudinal Study of the
53 INTERGROWTH-21st Project

54

55 **Short title:**

56 Fetal Growth Velocity Standards

57

58 **AJOG at a glance**

59 **A. Why was the study conducted**

60 To identify fetuses at risk of adverse outcomes because actual rates of skeletal and organ
61 growth differ across time, and insults at different time-points during pregnancy almost
62 certainly have differential effects on growth.

63 **B. What are the key findings**

64
65 We present fetal velocity standards using fetal data collected prospectively in a rigorous
66 scientific manner from low-risk women, whose newborns have been followed until 2 years
67 of age. We provide an App that can easily be used in clinical practice to evaluate changes
68 in fetal size as conditional velocity for a more refined assessment of fetal growth than is
69 possible at present

70

71
72 **C. What does this study add to what is already known**

73 These standards may be valuable if one wants to study the pathophysiology of fetal
74 growth comprehensively. They perfectly complement our existing fetal growth standards
75 (distance), which are already being used clinically in many settings.

77 **BACKGROUND:** Human growth is susceptible to damage from insults, particularly during
78 periods of rapid growth. Identifying those periods and the normative limits that are compatible
79 with adequate growth and development are the first key steps towards preventing impaired
80 growth.

81 **OBJECTIVE:** To construct international fetal growth velocity increment and conditional velocity
82 standards from 14 to 40 weeks' gestation based on the same cohort that contributed to the
83 INTERGROWTH-21st Fetal Growth Standards.

84 **STUDY DESIGN:** Prospective, longitudinal study of 4,321 low-risk pregnancies from eight
85 geographically diverse populations in the INTERGROWTH-21st Project with rigorous
86 standardization of all study procedures, equipment, and measurements that were performed by
87 trained ultrasonographers. Gestational age was accurately determined clinically and confirmed by
88 ultrasound measurement of crown-rump length at <14 weeks' gestation. Thereafter, the
89 ultrasonographers, who were masked to the values, measured the fetal head circumference
90 (HC), biparietal diameter (BPD), occipitofrontal diameter (OFD), abdominal circumference (AC)
91 and femur length (FL) in triplicate every 5 weeks (within 1 week either side) using identical
92 ultrasound equipment at each site (4-7 scans per pregnancy). Velocity increments across a
93 range of intervals between measures were modelled using fractional polynomial regression.

94 **RESULTS:** Peak velocity was observed at a similar gestational age: 16- and 17-weeks' gestation
95 for HC (12.2 mm/week), and 16 weeks' gestation for AC (11.8 mm/week) and FL (3.2 mm/week).
96 However, velocity growth slowed down rapidly for HC, BPD, OFD and FL, with an almost linear
97 reduction towards term that was more marked for FL. Conversely, AC velocity remained relatively
98 steady throughout pregnancy. The change in velocity with gestational age was more evident for
99 HC, BPD, OFD and FL than for AC when the change was expressed as a percentage of fetal size
100 at 40 weeks' gestation. We have also shown how to obtain accurate conditional fetal velocity
101 based on our previous methodological work.

102 **CONCLUSION:** The fetal skeleton and abdomen have different velocity growth patterns during
103 intrauterine life. Accordingly, we have produced international Fetal Growth Velocity Increment
104 Standards to complement the INTERGROWTH-21st Fetal Growth Standards so as to monitor
105 fetal wellbeing comprehensively worldwide. Fetal growth velocity curves may be valuable if one
106 wants to study the pathophysiology of fetal growth. We provide an App that can easily be used in
107 clinical practice to evaluate changes in fetal size as conditional velocity for a more refined
108 assessment of fetal growth than is possible at present (https://lxiao5.shinyapps.io/fetal_growth/).

109 Th Journal Pre-proof at
110 (<https://intergrowth21.tghn.org/standards-tools/>).
111

Journal Pre-proof

112 **In**
113 Fetal anthropometric measurements, assessed by ultrasound scanning during pregnancy, are
114 taken as an indirect means of assessing fetal size. Values are plotted on one of the many
115 reference charts available, which have been developed using a variety of methods and varying
116 scientific rigor.^{1, 2} Size measures at the extreme ends, e.g. below the 3rd, 5th or 10th centiles or
117 above the 90th, 95th or 97th centiles, of an often locally derived reference distribution, are typically
118 interpreted as markers of growth impairment for the purpose of identifying fetuses at increased
119 risk of adverse perinatal outcomes.

120 However, size and growth are not synonymous terms – a fact that is frequently ignored or
121 misunderstood.³⁻⁶ Size is an individual measure taken at a specific point in time; repeated size
122 measures represent distant variations in size. In contrast, growth is a change in a measure per unit
123 of time – hence, a dynamic process.^{3, 7} Specific charts for each objective should have been
124 purposely derived from several anthropometric measures obtained longitudinally from the same
125 fetuses and expressed as distance or velocity measures.^{5, 8-10} Charts should conform to the
126 recommendations of the World Health Organization (WHO) for monitoring human growth and be
127 based on the ‘prescriptive’ approach, i.e. they should be international standards, derived from
128 healthy populations that have minimal nutritional, environmental or socio-economic constraints on
129 growth.¹¹

130 To our knowledge, the only published international fetal growth charts that conform completely to
131 the WHO prescriptive recommendations are those constructed using data from the
132 INTERGROWTH-21st Fetal Growth Longitudinal Study (FGLS).¹²⁻¹⁴ However, the use of such
133 ‘distance’ growth charts in clinical practice may not be sufficient to identify fetuses at risk of
134 adverse outcomes because: 1) actual rates of skeletal and organ growth differ across time and 2)
135 insults at different time-points during pregnancy almost certainly have differential effects on the
136 growth and development of the skeleton and individual organs.¹⁵ It should, therefore, be self-
137 evident that the concept of the differential growth velocity of fetal structures is in conflict with the
138 practice of using single summary indicators of fetal growth, such as estimated fetal weight (EFW).
139 To illustrate the point, poor placental nutrient transfer in the second trimester of pregnancy leads
140 to early onset fetal growth restriction (FGR) including impaired skeletal growth,¹⁶ whilst in later
141 pregnancy it leads to depletion of fetal fat stores.¹⁷

142 Thus, to complement the existing international INTERGROWTH-21st Fetal Growth (*Distance*)
143 Standards,¹² we present here international Fetal Growth (*Velocity Increment and Conditional*
144 *Velocity*) Standards, based on the same serial ultrasound measures obtained from the FGLS
145 cohort. We also provide an easy to use App that enables assessment of velocity increment and
146 conditional velocity for fetal head circumference (HC), biparietal diameter (BPD), occipitofrontal

di: (https://lxiao5.shinyapps.io/fetal_growth/). The App is freely available with the other INTERGROWTH-21st tools at (<https://intergrowth21.tghn.org/standards-tools/>).

Materials & Methods

Design

INTERGROWTH-21st was a multicenter, population-based project, carried out between 2009 and 2016, in eight delimited urban areas: Pelotas, Brazil; Turin, Italy; Muscat, Oman; Oxford, UK; Seattle, WA, USA; Shunyi County, a suburban district of the Beijing municipality, China; the central area of the city of Nagpur (Central Nagpur), Maharashtra, India; and the Parklands suburb of Nairobi, Kenya.¹² At each study site, we recruited women with no clinically relevant obstetric, gynecological or medical history, who initiated antenatal care <14⁺⁰ weeks' gestation by menstrual dates and met the entry criteria of optimal health, nutrition, education and socio-economic status. This resulted in a group of educated, affluent, clinically healthy women, with adequate nutritional status, who by definition were at low risk of FGR and preterm birth. A detailed description of the entry criteria and definitions has been published previously.¹²

The last menstrual period (LMP) was used to calculate gestational age provided that: a) the date was certain; b) the woman had a regular 24-32 day menstrual cycle; c) she had not been using hormonal contraception or breastfeeding in the preceding 2 months, and d) any discrepancy between the gestational ages based on LMP and crown-rump length (CRL), measured by ultrasound at 9⁺⁰ to 13⁺⁶ weeks from the LMP was ≤ 7 days, using the formula described by Robinson & Fleming.¹⁸ To ensure that CRL measures were interpreted consistently, the Robinson & Fleming formula was loaded into all the study ultrasound machines; whenever another machine had to be used locally for CRL measurement, a conversion table extracted from the same formula was provided. The CRL technique was also standardized across sites and all ultrasonographers were uniformly trained.¹⁹

FGLS was one of the nine component studies of the INTERGROWTH-21st Project, which has been described in detail elsewhere.^{12-14, 20} Briefly, FGLS involved performing serial examinations with the same ultrasound machine (Philips HD-9, Philips Ultrasound, USA) every 5 weeks (within 1 week either side) after an initial scan <14 weeks' gestation that confirmed the certain clinical dates; hence, the possible ranges of scan visits were at 14-18, 19-23, 24-28, 29-33, 34-38 and 39-42 weeks' gestation. At each visit after 14 weeks' gestation, the fetal measures obtained were HC, BPD, OFD, AC and FL. Each parameter was measured in triplicate from three separately obtained images of each structure. These studies have provided robust evidence of the similarities in skeletal growth from early pregnancy to 2 years of age in the infants of healthy

182 w
183 neurodevelopment^{14, 20}

184 The measurement protocol, including masking the ultrasonographer to the values, and the unique
185 training, standardization and quality control procedures have been reported elsewhere²¹⁻²⁴. In
186 brief, ultrasonographers were recruited based on their technical experience, motivation, reliability
187 and ability to speak the local language(s). They underwent rigorous training consisting of
188 acquiring theoretical knowledge and familiarity with the study protocol, ultrasound machine and
189 operations manual, data collection and quality control measures. Centralized hands-on training
190 and initial standardization were also conducted.¹² In addition, site-specific standardization was
191 conducted at regular intervals by the Ultrasound Quality Control Unit, based in Oxford, to ensure
192 proper use of the ultrasound equipment, calibration and adherence to the protocol. A quality
193 control system was implemented throughout the study based on: 1) assessing the distributions of
194 the three masked measurements taken for HC, BPD, OFD, AC and FL at each scan and 2) the
195 Ultrasound Quality Control Unit taking a random 10% sample of all ultrasound images, assessing
196 their quality using a validated scoring system and remeasuring them.²⁴ Only after three
197 measurements of each structure were recorded was each average value revealed to the
198 ultrasonographer for clinical purposes. The reproducibility of the fetal ultrasound measurements
199 has been previously reported.²⁵

200 The cohort enrolled in FGLS was followed up to 2 years of age and evaluated for their skeletal
201 growth, nutrition, health and the WHO gross motor milestones.^{20, 26}

202 The INTERGROWTH-21st Project was approved by the Oxfordshire Research Ethics Committee
203 "C" (reference: 08/H0606/139), the research ethics committees of the individual participating
204 institutions, and the corresponding regional health authorities where the project was
205 implemented. Participants provided written consent to be involved in the study. All
206 documentation, protocols, data collection forms and clinical tools are freely available on the
207 INTERGROWTH-21st website (<https://intergrowth21.tghn.org/>).

209 **Statistical methodology**

210 The decision to pool the data from all the study sites to construct fetal velocity increment
211 standards was based on our detailed, previously published analyses of the same data,¹⁴ using
212 the strategy recommended in the WHO Multicentre Growth Reference Study,²⁷ that produced the
213 WHO Child Growth Standards.²⁸ Our overall aim was to produce velocity increments that change
214 smoothly with gestational age and maximize simplicity, without compromising model fit; we have,

considerations for the analysis of the FGLS data are described in detail elsewhere.^{29, 30}

Velocity increment

Velocity increment was calculated as the difference between two ultrasound measures denoted by Y_1 and Y_2 , divided by the time interval between them, i.e., t_1 , and t_2 , respectively.³¹⁻³⁴ The velocity increment rate of growth per week is therefore:

$$\text{Velocity increment} = (Y_2 - Y_1) / (t_2 - t_1) \text{ mm/week.}$$

Velocity increments per week were modelled as a function of gestational age at the mid-time-point between any pair of observations on a continuous scale using fractional polynomial regression.³⁵ To account for increasing variability with gestational age, the mean and standard deviation (SD) were modelled separately using fractional polynomial regression³⁵ of the best fitting powers for HC, BPD, OFD, AC and FL. To determine velocity increments, we analyzed pairs of observations taken during the course of the serial ultrasound examinations performed every 5 weeks (within 1 week either side).

Goodness of fit incorporated visual inspection of overall model fit by comparing empirical centiles (calculated per complete week of gestation, e.g. 38 weeks = 38^{+0} to 38^{+6}) to the fitted centiles, using quantile-quantile (q-q) plot of the residuals, plots of residuals vs. fitted values, and the distribution of fitted Z-scores across gestational ages.

The fitted models were used to obtain velocity centiles on the relative change over each gestational week. Velocity increments were computed as the average relative change for the average week-specific measurement. These velocities were determined across gestational ages from 16 to 40 weeks, and for each fetal biometry.

Conditional velocity

In the context of this paper, we considered conditional velocity as the rate of growth (often referred to as growth velocity) which evaluates velocity, based on the change in relative attained size between two time-points.^{34, 36} A velocity Z-score of zero denotes perfect tracking whereas one above or below zero represents faster or slower growth than expected between the specified times. However, an important consideration is the well-known phenomenon of regression to the mean³⁷ as many, but not all, small fetuses will on average 'catch-up' and many, but not all, large fetuses will 'catch-down'.³⁸ Regression to the mean has far-reaching implications,^{37, 39, 40} not often accounted for, especially when assessing velocity. The correlation coefficient is a direct measure of regression to the mean.^{38, 39, 41} The conditional standard deviation scores (cSDS) account for regression to the mean by adjusting for the correlation between the two time-points.³⁸

the correlation between any pair of fetal HC, BPD, OFD, AC or FL measures between 14 and 40 weeks' gestation has recently been published.⁴² In brief, to account for non-normality of fetal measurements, we applied a two-stage approach. The first stage involved finding a suitable transformation of the raw fetal measurements as the marginal distributions of ultrasound measurements were non-normal using LMS transformation⁴³ of three parameters (location, scale, and skewness using Box-Cox Cole-Green distribution⁴³) and four parameters (location, scale, skewness, and kurtosis using Box-Cox *t*-distribution⁴⁴ and Box-Cox power exponential distribution⁴⁵) to standardised deviations (Z-scores). In the second stage, a correlation model for a Gaussian process is fitted, yielding a correlation for any pair of observations made between 14 and 40 weeks of gestation. To model correlations, parametric and non-parametric models were used. Four exponential parametric models were applied and because growth measurements might have non-ignorable measurements errors, a nugget effect term for the exponential model was also explored, as well as two non-parametric models for modelling correlation. Further details are presented in a previous report.⁴²

We used the correlation coefficients from this work to calculate the fetal conditional velocity for HC, BPD, OFD, AC and FL using the cSDS approach.³⁸

The FGLS data were converted to Z-scores using the published international INTERGROWTH-21st Fetal Growth (*Distance*) Standards derived from the same data.¹² Let fetal biometry Z-scores be denoted by Z_1 and Z_2 at time-points t_1 and t_2 , and correlation coefficient r_{12} between them. The cSDS between the two time-points is given by:

$$\text{cSDS} = (Z_2 - r_{12} \times Z_1) / \sqrt{(1 - r_{12}^2)},^{38} \quad \text{Equation 1}$$

where $t_1 < t_2$, Z_1 is the Z-score at t_1 , Z_2 is the Z-score at t_2 , and r_{12} is the correlation coefficient between Z_1 and Z_2 .³⁸

All analyses were performed in STATA, version 11.2, software (StataCorp LP, College Station, Texas, USA) and R statistical software.

Results

Overall results

In the original FGLS, a total of 4,321 women had live singleton births in the absence of severe maternal conditions or congenital abnormalities detected by ultrasound or at birth; this forms the included study sample. The median number of ultrasound scans (excluding the dating scan) was 5.0 (mean = 4.9, SD = 0.8, range from 4 to 7) and 97% of women had ≥ 4 scans (mean = 5.0, SD

281 =
282 population was used for the present analysis.

283 The high protocol adherence meant that the intervals between adjacent measurements were
284 mostly 4- (n=3,836), 5- (n=8,871), or 6- (n=2,411) weeks, or intervals involving a combination or
285 multiples of the 4-, 5- and 6-week intervals: 8- (n=721), 9-(n=2,817), 10- (n=5,186), 11-
286 (n=1,932), and 12- (n=356) weeks. In total, 20,030 fetal measures were used to construct the
287 Fetal Growth Velocity Standards.

288 A scatter plot of increments in raw HC, AC, BPD, OFD and FL data (mm/week) and the fitted 3rd,
289 50th and 97th smoothed centiles according to gestational age (weeks) is shown in Figure 1 and
290 Supplementary Figure 1.

291 The baseline characteristics of the study cohort across the eight urban areas have previously
292 been shown to be very similar, which was expected because women were selected using the
293 same clinical and demographic criteria (supplementary Table 1). The pregnancy and perinatal
294 events for the complete cohort, which confirmed their status as healthy women at low risk of
295 impaired fetal growth have also been published before.¹² In addition, the infant cohort remained
296 healthy with adequate growth, motor development and associated behaviours up to 2 years of
297 age,^{20, 46} supporting its appropriateness for the construction of the INTERGROWTH-21st Fetal
298 Growth (*Distance*) Standards¹² and associated Preterm Postnatal Growth Standards.⁴⁷

299 **Velocity increments**

300 The rate of growth for HC was highest at 16- and 17-weeks' gestation (12.2 mm/week), and the
301 velocity slowed down with an almost linear reduction (9.7 mm/week at 28 weeks versus 6.1
302 mm/week at 35 weeks' gestation) towards term (Figure 1, Table 1A). For BPD, peak velocity was
303 observed at 19- and 20-weeks' gestation (3.2 mm/week) (Supplementary Figure 1, Table 1B).
304 OFD had an earlier observed peak velocity at 16 weeks' gestation (4.51 mm/week)
305 (Supplementary Figure 1, Table 1C). A similar pattern of growth was seen with the other skeletal
306 measure (FL). The rate of FL growth was highest very early in pregnancy at 16 weeks' gestation:
307 mean 3.2 mm/week, reduced to 2.2mm/week at 28 weeks and 1.8 mm/week at 34 weeks'
308 gestation (Figure 1, Table 1D). FL velocity decreased linearly with increasing gestational age.

309 Conversely, the velocity growth for AC (consisting of abdominal organs and subcutaneous fat)
310 was relatively steady across most gestational ages, from 16 weeks (mean 11.8 mm/week), to
311 10.4 mm/week at 28 weeks, to 9.7 mm/week at 34 weeks' gestation. This pattern is clearly
312 different from that of HC (Figure 1, Table 1E).

313 Figure 2 shows the velocity increment growth presentations of fetal HC, AC, and FL relative to
314 the expected attained size at 40 weeks' gestation according to the published international

weeks / 33.4 cm at 40 weeks) of the HC size at term has been reached by 33 weeks' gestation (Figure 2).

The change in velocity with gestational age was more clearly seen in the skeletal markers for HC, BPD, OFD and FL compared with AC when expressed as a percentage of size at 40 weeks' gestation¹² (Figure 2 and Supplementary Figure 2). AC gain is steady at around 3% per week (range: 2.7%, 3.4%) of the total size at term; HC gain is close to 4% of the term size per week at 16 weeks and <1% after 36 weeks' gestation (range: 0.8%, 3.7%). FL gain is highest in early pregnancy and decreases linearly with advancing gestational age (range: 2%, 4.5%).

Tables 1A-E present the predicted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles for velocity increments between 14 and 40 weeks' gestation for HC, BPD, OFD, AC and FL respectively to match the previously published Fetal Growth (*Distance*) Standards.¹² The corresponding equations for the mean and SD from the fractional polynomial regression models for each measure are presented in Table 2, allowing for calculations by readers of any desired centiles or Z-scores according to gestational age. For example, centiles can be calculated as mean \pm Z \times SD, where Z is -1.88, -1.645, -1.28, 0, 1.28, 1.645 and 1.88 for the 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles, respectively. Printable charts and related tools will be available free of any charge at <http://www.intergrowth.org.uk>.

Conditional velocity

We randomly selected measures across different gestational ages and used the fitted correlations and observed Z-scores¹² to illustrate conditional velocity (cSDS) for a single fetus according to gestational age. For demonstration purposes, we show in Figures 3A-D, four hypothetical fetal HC growth scenarios likely to be observed during pregnancy: a fetus that exhibits the expected average rate of growth throughout pregnancy (Scenario A); a fetus whose longitudinal pattern of growth exhibits possible microcephaly (Scenario B); a fetus whose pattern of growth is within 2 SD of an established fetal HC standard (Scenario C); and a fetus whose longitudinal pattern of growth exhibits possible macrosomia (Scenario D).

These calculations and visual illustrations are embedded in the R-shiny application (App) (<https://lxiao5.shinyapps.io/shinycalculator/>). In addition, the App converts fetal measures to Z-scores according to the international Fetal Growth (*Distance*) Standards of the INTERGROWTH-21st Project;¹² enables correlations to be calculated between any pair of fetal biometry measures to calculate conditional velocity (cSDS), and calculates velocity increments for HC, BPD, OFD, AC and FL (<https://lxiao5.shinyapps.io/shinycalculator/>).

Journal Pre-proof

350 **Comment**351 *Principal findings*

352
353 We have described growth velocity increment and estimated velocity standards, as well
354 as conditional velocity, using highly standardized ultrasound measures of the skeleton
355 and abdominal organs/fat of fetuses from the FGLS cohort of the INTERGROWTH-21st
356 Project. This is the same cohort from which not only the INTERGROWTH-21st Fetal
357 Growth (*Distance*) Standards were developed,¹² but also the international standards for:
358 i) Symphysis-Fundal Height,⁴⁸ ii) Gestational Weight Gain,⁴⁹ iii) Early and Late
359 Pregnancy Dating,⁵⁰ iv) Estimated Fetal Weight,⁵¹ v) Newborn Body Composition,⁵² and
360 vi) the Postnatal Growth of Preterm Infants.⁴⁷ Hence, the new velocity standards allow,
361 for the first time, distance and velocity growth *in utero* to be assessed using longitudinal
362 growth trajectories from the same international populations of pregnant women at low
363 risk for adverse health, nutritional and environmental factors, i.e. prescriptive
364 populations.

365 In addition, for the first time in the obstetric ultrasound literature, we followed up the
366 cohort until 2 years of age and showed that the mean skeletal growth of the infants
367 participating in FGLS was well within the WHO Child Growth Standards (50th centile for
368 HC, 49th centile for length, and 58th centile for weight). These findings strongly suggest
369 that the fetal growth velocity increments described here are likely to be observed in
370 healthy populations worldwide.

371 *Results*

372
373 Our results show that peak growth velocity is observed between 16- and 17-weeks'
374 gestation for the fetal skeleton (HC and FL) and abdomen (AC); however, the observed
375 patterns were markedly different. OFD had an earlier peak velocity at 16 weeks
376 compared to 19- and 20- weeks' gestation for BPD, which implies that the fetal head
377 may have a rate of growth that promotes a slightly disproportionate shape to
378 accommodate certain brain structures.

379 Growth velocity slowed down rapidly for HC and FL and at an almost linear rate in the
380 case of FL; by contrast, it remained steady throughout pregnancy for AC. In addition,
381 there was larger variability in the AC velocity values, compared to those for HC and FL,
382 especially in the second half of pregnancy. Taken together, the findings show that

383 overall skeletal growth is a biological process that has the highest rate of growth in the
384 first part of pregnancy; linear skeletal growth (FL) is even more pronounced.

385 How do our results compare with previously published studies? For HC, Deter and
386 colleagues, using the Rossavik growth model in a cohort of 20 fetuses,⁵³ reported an
387 earlier peak velocity at 14 weeks (14 mm/week), which decreased to 9 mm/week at 30
388 weeks and 5 mm/week at 38 weeks' gestation.⁵⁴ Similarly, for AC, peak velocity was
389 earlier (12 mm/week at 14 weeks and reduced to 11 mm/week at 30 weeks of
390 gestation), Todros and colleagues, applying a growth model similar to Rossavik's in
391 4,758 fetuses of physiological pregnancies found that the peak velocity was at around
392 16 weeks' gestation for both HC and BPD (63). Similarly, Guihard-Costa and
393 colleagues reported multiphasic patterns of growth velocity with a common peak of
394 velocity at about 16 weeks of gestation, and no sex differences in growth velocity⁵⁵.
395 Bertino and colleagues reported similar findings to ours: in 238 fetuses, peak velocity
396 was reached at 17.3 weeks' gestation with a rapid increase in the early part of the
397 second trimester, which then decreased up until the end of pregnancy.⁵⁶

398 A number of studies using different selection criteria, hospital populations, ultrasound
399 equipment and methodologies have reported a decrease in FL linear growth velocity by
400 gestational age.⁵⁷⁻⁵⁹ However, it is important to bear in mind that the populations
401 studied were not equivalent and that FL is measured differently by modern equipment;
402 hence, the values are not entirely comparable.⁶⁰ This is an important issue because
403 hospitals are still using FL charts based on equipment that is no longer in use, which
404 increases the risk of misclassifying fetuses.

405 Recently, Grantz and colleagues studied the relationship between fetal growth velocity
406 and self-reported maternal ethnicity.⁶¹ The findings were similar to the present study: FL
407 velocity was between 3.4 to 3.5 mm/week at 16 weeks (3.2 mm/week in our study), 2.2
408 mm/week at 28 weeks (2.2 mm/week in our study), and 1.8 to 1.9 mm/ week at 34
409 weeks' gestation (1.8 mm/week in our study). Therefore, as the INTERGROWTH-21st
410 Project has clearly demonstrated, fetal linear skeletal growth velocity seems to be very
411 similar regardless of the mother's geographical location, country of origin or self-
412 reported ethnicity, which adds considerable support to the concept that growth amongst
413 healthy, low-risk fetuses is universal.⁶²

414 AC, which is an indicator of abdominal organ growth (mostly liver and subcutaneous
415 fat), is strongly influenced by the underlying nutritional status of the population being
416 studied. In developed countries and in countries suffering from the “double burden of
417 malnutrition”, where a large proportion of the population is in the midst of the obesity
418 epidemic, it is becoming increasingly clear that overweight/obesity is often initiated *in*
419 *utero*.⁶³ Hence, comparing AC growth in previous studies^{56, 64} with the FGLS cohort of
420 healthy, low-risk women, is a less relevant question given that fetal AC values in
421 unselected populations are influenced by the distribution of maternal fat-related
422 markers, i.e. the fetal AC may be larger in obese women than in those with a normal
423 BMI.⁶⁵

424 Interestingly, Grantz and colleagues, in a US population, reported AC velocity values
425 early in pregnancy that were very similar to our study: 11.7 to 12.2 mm/week at 16
426 weeks (11.8 mm/week in our study) and 10.3 to 10.9 mm/week at 28 weeks’ gestation
427 (10.4 mm/week in our study).⁶¹ However, in the third trimester, there was clear evidence
428 of AC over-growth: 10.1 to 10.8 mm/week at 34 weeks’ gestation versus 9.7 mm/week
429 in our study. In short, fat may be deposited in the fetal abdomen faster in some
430 populations compared to others resulting in over-weight, despite similar skeletal growth
431 velocities.

432 *Clinical implications*

433

434 Our analysis of skeletal and abdominal velocity increments, expressed as a percentage
435 of attained fetal size at 40 weeks’ gestation, also showed differential growth velocity
436 patterns. This finding has important clinical consequences because of how EFW is
437 utilized in obstetric practice. Based on the present findings and taking into account
438 basic analytic principles, summary measures such as EFW should not be used if there
439 is evidence of biological heterogeneity among the parameters to be combined. Thus,
440 the observation that similar EFW estimations can be obtained from different
441 permutations of HC, AC and FL values may explain the large errors often seen in EFW
442 values regardless of which equation is used.^{66, 67}

443 The biological significance of the heterogeneity in the velocity and timing of fetal growth
444 is best appreciated by examining how an intrauterine insult, such as infection with the
445 Zika virus (ZIKV), can have varying effects at different stages of pregnancy. Infection in

446 the first trimester has clearly been associated with massive disruption to brain
447 development and a decrease in the rate of head growth, resulting in microcephaly.⁶⁸
448 However, brain damage can also arise from infection late in pregnancy despite head
449 size remaining within 'normal' limits.^{69, 70} Certainly, in our dataset, 90% of the HC at
450 term has been reached by 33 weeks' gestation, i.e. HC values at birth and at 33 weeks'
451 gestation are very similar. Therefore, ZIKV infection after 33 weeks' gestation may still
452 lead to brain damage but the effect on skull size will be limited, which means that
453 diagnosing ZIKV infection based solely on the presence of microcephaly at birth will be
454 associated with a false negative rate. Interestingly, we can extend this type of
455 comparison into childhood. The mean HC of the same cohort at 2 years of age was
456 47.8 cm; although we acknowledge differences in measurement techniques, on
457 average, two-thirds of a 2 year-old child's HC is attained by 33 weeks' gestation.

458 *Strengths and limitations*

459

460 The present findings could have important implications for clinical practice as improved
461 assessment of fetal growth patterns could potentially lead to more personalized
462 antenatal care. In other words, the use of the standards described here could help to
463 distinguish healthy from disturbed fetal growth for both the management of individual
464 pregnancies and for screening purposes. However, there are practical challenges. A
465 similar approach has been advocated in the past for monitoring child growth; however,
466 it has not been adopted in routine practice largely because the calculations are complex
467 and the results are difficult to interpret. To illustrate the point, the choice of interval
468 length between measures affects the results: the shorter the interval, the higher the
469 variability in growth and measurement error compared with the actual growth. Guihard-
470 Costa and colleagues recommend a 3-week interval as the minimal time interval in
471 which the growth rate may be statistically significant, taking into account the number of
472 cases, the minute fluctuations of growth rate in short periods and the individual
473 variability of growth velocity⁵⁵. However, extending the time interval loses the benefit of
474 assessing velocity especially during the third trimester when the peak of growth has
475 passed for skeletal markers, AC variability is very large and birth is soon likely to occur.
476 Frequent ultrasound measurements are also not presently recommended for routine
477 antenatal care and have implications for cost, staff numbers and workload. Our robust
478 statistical modelling work of the correlation of fetal biometry measurements using a two-

479 stage approach addressed at least some of these limitations by enabling the calculation
480 of fetal biometry correlations for any pair of observations between 14 and 40 weeks,
481 and is independent of time interval.⁴²

482 To facilitate the use of the standards described here, we have provided an easy to use
483 R shiny App (freely available at https://lxiao5.shinyapps.io/fetal_growth/) for assessing
484 conditional velocity if repeat ultrasound measures are clinically indicated. We believe
485 that both distance and velocity assessments of fetal growth would help clinicians to
486 detect fetuses at risk of a growth abnormality. There are clinical advantages of
487 assessing growth using conditional velocity. For instance, a fetus may not meet its
488 growth trajectory, yet not fall below a cut-off centile (such as the 10th); however, a size
489 chart would not identify that fetus as small for gestational age, despite its evident poor
490 growth over time.

491 *Research implications*

492
493 The present findings offer new avenues for both clinical and life sciences research. It
494 may now be possible to identify more refined fetal growth phenotypes (or ‘fetotypes’),
495 matching those described for the neonate, which may be associated with certain child
496 health outcomes. Hence, we encourage health professionals worldwide to join us in
497 determining the clinical significance of deviations from optimal skeletal and fat-
498 dependent growth by conducting research to establish if routine fetal growth velocity
499 assessment can improve health outcomes.⁷¹ External assessment of the findings in
500 daily practice, including the implications of growth above or below the standards are
501 areas for future research. The potential pathophysiologic significance of the growth
502 velocity patterns identified here should also prompt a renewed focus on research into
503 the underlying cellular and molecular mechanisms responsible for fetal growth.

504 *Conclusions*

505

506 In summary, we have shown that fetal growth velocity increment is highest in the early
507 part of the second trimester, and decreases with gestational age for skeletal structures,
508 and that there is a clear continuous pattern throughout pregnancy for fat-related
509 markers such as AC. Lastly, we have constructed international Fetal Growth *Velocity*
510 *Increment* Standards and conditional velocity to complement the set of tools produced

511 by the INTERGROWTH-21st Project.¹² A free, simple-to-use, online clinical tool is
512 presented here enabling calculation of fetal growth velocity throughout pregnancy.

513

514

515

516

517

518

519

520

521

522

523

524

525 References

- 526 1. NAPOLITANO R, DHAMI J, OHUMA E, et al. Pregnancy dating by fetal crown-rump length: a
527 systematic review of charts. BJOG 2014;121:556-65.
- 528 2. IOANNOU C, TALBOT K, OHUMA E, et al. Systematic review of methodology used in ultrasound
529 studies aimed at creating charts of fetal size. BJOG 2012;119:1425-39.
- 530 3. ALTMAN DG, HYTTEN FE. Intrauterine growth retardation: let's be clear about it. British journal of
531 obstetrics and gynaecology 1989;96:1127-32.
- 532 4. WILCOX AJ. Birth weight, gestation, and the fetal growth curve. American journal of obstetrics
533 and gynecology 1981;139:863-7.
- 534 5. SALOMON LJ. Early fetal growth: concepts and pitfalls. Ultrasound in obstetrics & gynecology : the
535 official journal of the International Society of Ultrasound in Obstetrics and Gynecology
536 2010;35:385-9.
- 537 6. MARCONI AM, RONZONI S, BOZZETTI P, VAILATI S, MORABITO A, BATTAGLIA FC. Comparison of fetal and
538 neonatal growth curves in detecting growth restriction. Obstetrics and gynecology
539 2008;112:1227-34.
- 540 7. DETER RL, HARRIST RB, HADLOCK FP, CARPENTER RJ. The use of ultrasound in the assessment of
541 normal fetal growth: a review. J Clin Ultrasound 1981;9:481-93.
- 542 8. ALTMAN DG, CHITTY LS. Design and analysis of studies to derive charts of fetal size. Ultrasound
543 Obstet Gynecol 1993;3:378-84.
- 544 9. ROYSTON P, ALTMAN DG. Design and analysis of longitudinal studies of fetal size. Ultrasound
545 Obstet Gynecol 1995;6:307-12.
- 546 10. ALTMAN DG, CHITTY LS. Charts of fetal size: 1. Methodology. Br J Obstet Gynaecol 1994;101:29-34.
- 547 11. WHO. An evaluation of infant growth: the use and interpretation of anthropometry in infants.
548 WHO Working Group on Infant Growth. Bull World Health Organ 1995;73:165-74.

- 549 12. PAPAGEORGHIOU AT, OHUMA EO, ALTMAN DG, et al. International standards for fetal growth based
550 on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-
551 21st Project. *Lancet* 2014;384:869-79.
- 552 13. VILLAR J, ALTMAN D, PURWAR M, et al. The objectives, design and implementation of the
553 INTERGROWTH-21st Project. *BJOG: An International Journal of Obstetrics & Gynaecology*
554 2013;120:9-26.
- 555 14. VILLAR J, PAPAGEORGHIOU AT, PANG R, et al. The likeness of fetal growth and newborn size across
556 non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal
557 Study and Newborn Cross-Sectional Study. *Lancet Diabetes Endocrinol* 2014;2:781-92.
- 558 15. FOWDEN AL, GIUSSANI DA, FORHEAD AJ. Intrauterine programming of physiological systems: causes
559 and consequences. *Physiology (Bethesda, Md)* 2006;21:29-37.
- 560 16. PAPAGEORGHIOU AT, FRATELLI N, LESLIE K, Bhide A, THILAGANATHAN B. Outcome of fetuses with
561 antenatally diagnosed short femur. *Ultrasound in obstetrics & gynecology : the official journal of*
562 *the International Society of Ultrasound in Obstetrics and Gynecology* 2008;31:507-11.
- 563 17. VILLAR J, BELIZAN JM. The timing factor in the pathophysiology of the intrauterine growth
564 retardation syndrome. *Obstet Gynecol Surv* 1982;37:499-506.
- 565 18. ROBINSON HP, FLEMING JE. A critical evaluation of sonar "crown-rump length" measurements. *Br J*
566 *Obstet Gynaecol* 1975;82:702-10.
- 567 19. IOANNOU C, SARRIS I, HOCH L, et al. Standardisation of crown-rump length measurement. *BJOG*
568 2013;120 Suppl 2:38-41.
- 569 20. VILLAR J, CHEIKH ISMAIL L, STAINES URIAS E, et al. The satisfactory growth and development at 2
570 years of age of the INTERGROWTH-21(st) Fetal Growth Standards cohort support its
571 appropriateness for constructing international standards. *American journal of obstetrics and*
572 *gynecology* 2018;218:S841-S54.e2.
- 573 21. CAVALLARO A, ASH ST, NAPOLITANO R, et al. Quality control of ultrasound for fetal biometry: results
574 from the INTERGROWTH-21st Project. *Ultrasound in obstetrics & gynecology : the official*
575 *journal of the International Society of Ultrasound in Obstetrics and Gynecology* 2018;52:332-39.
- 576 22. PAPAGEORGHIOU AT, SARRIS I, IOANNOU C, et al. Ultrasound methodology used to construct the fetal
577 growth standards in the INTERGROWTH-21st Project. *BJOG: An International Journal of*
578 *Obstetrics & Gynaecology* 2013;120:27-32.
- 579 23. SARRIS I, IOANNOU C, DIGHE M, et al. Standardization of fetal ultrasound biometry measurements:
580 improving the quality and consistency of measurements. *Ultrasound in obstetrics & gynecology*
581 *: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*
582 2011;38:681-7.
- 583 24. SARRIS I, IOANNOU C, OHUMA EO, et al. Standardisation and quality control of ultrasound
584 measurements taken in the INTERGROWTH-21st Project. *BJOG* 2013;120 Suppl 2:33-7.
- 585 25. SARRIS I, IOANNOU C, DIGHE M, et al. Standardization of fetal ultrasound biometry measurements:
586 improving the quality and consistency of measurements. *Ultrasound in Obstetrics & Gynecology*
587 2011;38:681-87.
- 588 26. WHO Motor Development Study: windows of achievement for six gross motor development
589 milestones. *Acta paediatrica (Oslo, Norway : 1992) Supplement* 2006;450:86-95.
- 590 27. DE ONIS M, GARZA C, VICTORA CG, ONYANGO AW, FRONGILLO EA, MARTINES J. The WHO Multicentre
591 Growth Reference Study: planning, study design, and methodology. *Food Nutr Bull* 2004;25:S15-
592 26.
- 593 28. DE ONIS M, GARZA C, ONYANGO AW, MARTORELL R. WHO Child Growth Standards. *Acta Paediatr*
594 *Suppl* 2006;450:1-101.
- 595 29. OHUMA EO, ALTMAN DG. Statistical methodology for constructing gestational age-related charts
596 using cross-sectional and longitudinal data: The INTERGROWTH-21st project as a case study.
597 2019; 38: 3507– 3526.

- 598 30. ALTMAN D, OHUMA E. Statistical considerations for the development of prescriptive fetal and
599 newborn growth standards in the INTERGROWTH-21st Project. *BJOG: An International Journal*
600 *of Obstetrics & Gynaecology* 2013;120:71-76.
- 601 31. HEALY MJR, YANG M, TANNER JM, ZUMRAWI FY. The use of short-term increments in length to
602 monitor growth in infancy. In: Waterlow JC, ed. *Linear growth retardation in less developed*
603 *countries*. New York: Vevey/Raven Press Ltd, 1988.
- 604 32. BORYSLAWSKI K. Structure of monthly increments of length, weight and head circumference in the
605 first year: a pure longitudinal study of 200 Wroclaw infants. *Annals of human biology*
606 1988;15:205-12.
- 607 33. THOMPSON H. Data on the growth of children during the first year after birth. *Hum Biol*
608 1951;23:75-92.
- 609 34. OWEN P, DONNET ML, OGSTON SA, CHRISTIE AD, HOWIE PW, PATEL NB. Standards for ultrasound fetal
610 growth velocity. *BJOG: An International Journal of Obstetrics & Gynaecology* 1996;103:60-69.
- 611 35. ROYSTON P, ALTMAN DG. Regression using fractional polynomials of continuous covariates:
612 Parsimonious parametric modelling. *Journal of the Royal Statistical Society Series C (Applied*
613 *Statistics)* 1994;43:429-67.
- 614 36. COLE TJ. Presenting information on growth distance and conditional velocity in one chart:
615 practical issues of chart design. *Stat Med* 1998;17:2697-707.
- 616 37. GALTON F. Regression towards mediocrity in hereditary stature. *Journal of the Anthropological*
617 *Institute of Great Britain and Ireland* 1886:246-63.
- 618 38. COLE TJ. Conditional reference charts to assess weight gain in British infants. *Archives of Disease*
619 *in Childhood* 1995;73:8-16.
- 620 39. HEALY MJ, GOLDSTEIN H. Regression to the mean. *Annals of human biology* 1978;5:277-80.
- 621 40. BLAND JM, ALTMAN DG. *Statistics Notes: Some examples of regression towards the mean. BMJ*
622 *(Clinical research ed)* 1994;309:780.
- 623 41. WRIGHT CM, MATTHEWS JNS, WATERSTON A, AYNSLEY-GREEN A. What is a normal rate of weight gain
624 in infancy? *Acta Pædiatrica* 1994;83:351-56.
- 625 42. FENG Y, XIAO L, LI C, CHEN S, OHUMA E. Correlation models for monitoring fetal growth. *Stat*
626 *Methods Med Res* 2020.
- 627 43. COLE TJ, GREEN PJ. Smoothing reference centile curves: The lms method and penalized likelihood.
628 *Statistics in Medicine* 1992;11:1305-19.
- 629 44. RIGBY RA, STASINOPOULOS DM. Using the Box-Cox t distribution in GAMLSS to model skewness and
630 kurtosis. *Statistical Modelling* 2006;6:209-29.
- 631 45. RIGBY RA, STASINOPOULOS DM. Smooth centile curves for skew and kurtotic data modelled using
632 the Box-Cox power exponential distribution. *Statistics in Medicine* 2004;23:3053-76.
- 633 46. VILLAR J, FERNANDES M, PURWAR M, et al. Neurodevelopmental milestones and associated
634 behaviours are similar among healthy children across diverse geographical locations. *Nature*
635 *Communications* 2019;10:511.
- 636 47. VILLAR J, GIULIANI F, BHUTTA ZA, et al. Postnatal growth standards for preterm infants: the Preterm
637 Postnatal Follow-up Study of the INTERGROWTH-21st Project. *Lancet Glob Health* 2015;3:e681-
638 91.
- 639 48. PAPAGEORGHIOU AT, OHUMA EO, GRAVETT MG, et al. International standards for symphysis-fundal
640 height based on serial measurements from the Fetal Growth Longitudinal Study of the
641 INTERGROWTH-21st Project: prospective cohort study in eight countries. *BMJ* 2016;355:i5662.
- 642 49. CHEIKH ISMAIL L, BISHOP DC, PANG R, et al. Gestational weight gain standards based on women
643 enrolled in the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project: a
644 prospective longitudinal cohort study. *BMJ* 2016;352:i555.
- 645 50. PAPAGEORGHIOU AT, KENNEDY SH, SALOMON LJ, et al. International standards for early fetal size and
646 pregnancy dating based on ultrasound measurement of crown-rump length in the first trimester
647 of pregnancy. *Ultrasound Obstet Gynecol* 2014;44:641-8.

- 648 51. STIRNEMANN J, VILLAR J, SALOMON LJ, et al. International estimated fetal weight standards of the
649 INTERGROWTH-21st Project. *Ultrasound Obstet Gynecol* 2017;49:478-86.
- 650 52. VILLAR J, PUGLIA FA, FENTON TR, et al. Body composition at birth and its relationship with neonatal
651 anthropometric ratios: the newborn body composition study of the INTERGROWTH-21st
652 Project. *Pediatr Res* 2017;82:305-16.
- 653 53. DETER RL, ROSSAVIK IK. A simplified method for determining individual growth curve standards.
654 *Obstet Gynecol* 1987;70:801-6.
- 655 54. DETER RL, HARRIST RB. Growth standards for anatomic measurements and growth rates derived
656 from longitudinal studies of normal fetal growth. *J Clin Ultrasound* 1992;20:381-8.
- 657 55. GUIHARD-COSTA A-M, DROULLÉ P, LARROCHE J-C. Growth velocity of the biparietal diameter,
658 abdominal transverse diameter and femur length in the fetal period. *Early Human Development*
659 1991;27:93-102.
- 660 56. BERTINO E, DI BATTISTA E, BOSSI A, et al. Fetal growth velocity: kinetic, clinical, and biological
661 aspects. *Arch Dis Child Fetal Neonatal Ed* 1996;74:F10-5.
- 662 57. ELEJALDE BR, DE ELEJALDE MM. The prenatal growth of the human body determined by the
663 measurement of bones and organs by ultrasonography. *Am J Med Genet* 1986;24:575-98.
- 664 58. O'BRIEN GD, QUEENAN JT. Growth of the ultrasound fetal femur length during normal pregnancy.
665 Part I. *Am J Obstet Gynecol* 1981;141:833-7.
- 666 59. BRONS JT, VAN GEIJN HP, BEZEMER PD, NAUTA JP, ARTS NF. The fetal skeleton; ultrasonographic
667 evaluation of the normal growth. *Eur J Obstet Gynecol Reprod Biol* 1990;34:21-36.
- 668 60. OKLAND I, BJAUSTAD TG, JOHANSEN TF, GJESSING HK, GROTTUM P, EIK-NES SH. Narrowed beam width in
669 newer ultrasound machines shortens measurements in the lateral direction: fetal measurement
670 charts may be obsolete. *Ultrasound Obstet Gynecol* 2011;38:82-7.
- 671 61. GRANTZ KL, KIM S, GROBMAN WA, et al. Fetal growth velocity: the NICHD fetal growth studies. *Am J*
672 *Obstet Gynecol* 2018;219:285 e1-85 e36.
- 673 62. PAPAGEORGHIOU AT, KENNEDY SH, SALOMON LJ, et al. The INTERGROWTH-21(st) fetal growth
674 standards: toward the global integration of pregnancy and pediatric care. *American journal of*
675 *obstetrics and gynecology* 2018;218:S630-s40.
- 676 63. HIRST JE, VILLAR J, PAPAGEORGHIOU AT, OHUMA E, KENNEDY SH. Preventing childhood obesity starts
677 during pregnancy. *Lancet* 2015;386:1039-40.
- 678 64. TODROS T, FERRAZZI E, GROLI C, et al. Fitting growth curves to head and abdomen measurements of
679 the fetus: a multicentric study. *J Clin Ultrasound* 1987;15:95-105.
- 680 65. ZHANG C, HEDIGER ML, ALBERT PS, et al. Association of Maternal Obesity With Longitudinal
681 Ultrasonographic Measures of Fetal Growth: Findings From the NICHD Fetal Growth Studies-
682 Singletons. *JAMA Pediatr* 2018;172:24-31.
- 683 66. DUDLEY NJ. A systematic review of the ultrasound estimation of fetal weight. *Ultrasound in*
684 *obstetrics & gynecology : the official journal of the International Society of Ultrasound in*
685 *Obstetrics and Gynecology* 2005;25:80-9.
- 686 67. ZHANG J, KIM S, GREWAL J, ALBERT PS. Predicting large fetuses at birth: do multiple ultrasound
687 examinations and longitudinal statistical modelling improve prediction? *Paediatr Perinat*
688 *Epidemiol* 2012;26:199-207.
- 689 68. MOLNAR Z, KENNEDY S. Neurodevelopmental disorders: Risks of Zika virus during the first
690 trimester of pregnancy. *Nat Rev Neurol* 2016;12:315-6.
- 691 69. HONEIN MA, DAWSON AL, PETERSEN EE, et al. Birth defects among fetuses and infants of US women
692 with evidence of possible Zika Virus infection during pregnancy. *JAMA* 2017;317:59-68.
- 693 70. FRANCA GV, SCHULER-FACCINI L, OLIVEIRA WK, et al. Congenital Zika virus syndrome in Brazil: a case
694 series of the first 1501 livebirths with complete investigation. *Lancet* 2016;388:891-7.
- 695 71. ROMERO R, DETER R. Should serial fetal biometry be used in all pregnancies? *Lancet*
696 2015;386:2038-40.
- 697

698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720

Journal Pre-proof

721 **Source of funding**

722 This project was supported by a generous grant from the Bill & Melinda Gates
723 Foundation (Grant no. 49038) to the University of Oxford, for which we are very

724 grateful. ATP is supported by the Oxford Partnership Comprehensive Biomedical
725 Research Centre with funding from the NIHR Biomedical Research Centre (BRC)
726 funding scheme. All authors report no conflict of interest.

727

728 **Acknowledgements**

729 We thank the Health Authorities in Pelotas, Brazil; Beijing, China; Nagpur, India; Turin,
730 Italy; Nairobi, Kenya; Muscat, Oman; Oxford, UK; and Seattle, WA, USA, who helped
731 with the project by allowing participation of these study sites as collaborating centers.
732 We thank Philips Healthcare for providing the ultrasound equipment and technical
733 assistance throughout the project and MedSciNet UK for setting up the
734 INTERGROWTH-21st website and for the development, maintenance and support of the
735 online data management system. We also thank the parents and infants who
736 participated in the studies and the more than 200 members of the research teams who
737 made the implementation of this project possible.

738 The participating hospitals included: Brazil, Pelotas (Hospital Miguel Piltcher, Hospital
739 São Francisco de Paula, Santa Casa de Misericórdia de Pelotas, and Hospital Escola
740 da Universidade Federal de Pelotas); China, Beijing (Beijing Obstetrics and Gynecology
741 Hospital, Shunyi Maternal and Child Health Centre, and Shunyi General Hospital);
742 India, Nagpur (Ketkar Hospital, Avanti Institute of Cardiology, Avantika Hospital,
743 Gurukrupa Maternity Hospital, Mulik Hospital and Research Centre, Nandlok Hospital,
744 Om Women's Hospital, Renuka Hospital and Maternity Home, Saboo Hospital,
745 Brajmonhan Taori Memorial Hospital, and Somani Nursing Home); Kenya, Nairobi (Aga
746 Khan University Hospital, MP Shah Hospital, and Avenue Hospital); Italy, Turin
747 (Ospedale Infantile Regina Margherita Sant' Anna and Azienda Ospedaliera Ordine
748 Mauriziano); Oman, Muscat (Khoula Hospital, Royal Hospital, Wattayah Obstetrics and
749 Gynaecology Poly Clinic, Wattayah Health Centre, Ruwi Health Centre, Al-Ghoubra
750 Health Centre, and Al-Khuwair Health Centre); UK, Oxford (John Radcliffe Hospital)
751 and USA, Seattle (University of Washington Hospital, Swedish Hospital, and
752 Providence Everett Hospital). Full acknowledgment of all those who contributed to the
753 development of the INTERGROWTH-21st Project are online and in the appendix
754 (below).

755

756

757 **Members of the International Fetal and Newborn Growth Consortium for the**
758 **21st Century (INTERGROWTH-21st) and its Committees**

759

760 **Scientific Advisory Committee**

761 M Katz (Chair from January 2011), MK Bhan, C Garza, S Zaidi, A Langer, PM Rothwell
762 (from February 2011), Sir D Weatherall (Chair until December 2010).

763

764 **Steering Committee**

765 ZA Bhutta (Chair), J Villar (Principal Investigator), S Kennedy (Project Director), DG
766 Altman, FC Barros, E Bertino, F Burton, M Carvalho, L Cheikh Ismail, WC Chumlea,
767 MG Gravett, YA Jaffer, A Lambert, P Lumbiganon, JA Noble, RY Pang, AT
768 Papageorghiou, M Purwar, J Rivera, C Victora.

769

770 **Executive Committee**

771 J Villar (Chair), DG Altman (deceased 2018), ZA Bhutta, L Cheikh Ismail, S Kennedy, A
772 Lambert, JA Noble, AT Papageorghiou.

773

774 **Project Coordinating Unit**

775 J Villar (Head), S Kennedy, L Cheikh Ismail, A Lambert, AT Papageorghiou, M Shorten,
776 L Hoch (until May 2011), HE Knight (until August 2011), EO Ohuma (from September
777 2010), C Cosgrove (from July 2011), I Blakey (from March 2011).

778

779 **Data Analysis Group**

780 DG Altman (Head), EO Ohuma, J Villar.

781

782 **Data Management Group**

783 DG Altman (Head), F Roseman, N Kunnawar, SH Gu, JH Wang, MH Wu, M
784 Domingues, P Gilli, L Juodvirsiene, L Hoch (until May 2011), N Musee (until June
785 2011), H Al-Jabri (until October 2010), S Waller (until June 2011), C Cosgrove (from
786 July 2011), D Muninzwa (from October 2011), EO Ohuma (from September 2010), D
787 Yellappan (from November 2010), A Carter (from July 2011), D Reade (from June
788 2012), R Miller (from June 2012).

789 **Ultrasound Group**

790 AT Papageorgiou (Head), L Salomon (Senior external advisor), A Leston, A Mitidieri, F
791 Al-Aamri, W Paulsene, J Sande, WKS Al-Zadjali, C Batiuk, S Bornemeier, M Carvalho,
792 M Dighe, P Gaglioti, N Jacinta, S Jaiswal, JA Noble, K Oas, M Oberto, E Olearo, MG
793 Owende, J Shah, S Sohoni, T Todros, M Venkataraman, S Vinayak, L Wang, D Wilson,
794 QQ Wu, S Zaidi, Y Zhang, P Chamberlain (until September 2012), D Danelon (until July
795 2010), I Sarris (until June 2010), J Dhama (until July 2011), C Ioannou (until February
796 2012), CL Knight (from October 2010), R Napolitano (from July 2011), S Wanyonyi
797 (from May 2012), C Pace (from January 2011), V Mkrtychyan (from June 2012).

798

799 **Anthropometry Group**

800 L Cheikh Ismail (Head), WC Chumlea (Senior external advisor), F Al-Habsi, ZA Bhutta,
801 A Carter, M Alija, JM Jimenez-Bustos, J Kizidio, F Puglia, N Kunnawar, H Liu, S Lloyd,
802 D Mota, R Ochieng, C Rossi, M Sanchez Luna, YJ Shen, HE Knight (until August
803 2011), DA Rocco (from June 2012), IO Frederick (from June 2012).

804

805 **Neonatal Group**

806 ZA Bhutta (Head), E Albernaz, M Batra, BA Bhat, E Bertino, P Di Nicola, F Giuliani, I
807 Rovelli, K McCormick, R Ochieng, RY Pang, V Paul, V Rajan, A Wilkinson, A Varalda
808 (from September 2012).

809

810 **Environmental Health Group**

811 B Eskenazi (Head), LA Corra, H Dolk, J Golding, A Matijasevich, T de Wet, JJ Zhang, A
812 Bradman, D Finkton, O Burnham, F Farhi.

813

814 **Participating countries and local investigators**

815 *Brazil:* FC Barros (Principal Investigator), M Domingues, S Fonseca, A Leston, A
816 Mitidieri, D Mota, IK Sclowitz, MF da Silveira.

817 *China:* RY Pang (Principal Investigator), YP He, Y Pan, YJ Shen, MH Wu, QQ Wu, JH
818 Wang, Y Yuan, Y Zhang.

819 *India:* M Purwar (Principal Investigator), A Choudhary, S Choudhary, S Deshmukh, D
820 Dongaonkar, M Ketkar, V Khedikar, N Kunnawar, C Mahorkar, I Mulik, K Saboo, C
821 Shembekar, A Singh, V Taori, K Tayade, A Somani.

822 *Italy:* E Bertino (Principal Investigator), P Di Nicola, M Frigerio, G Gilli, P Gilli, M Giolito,
823 F Giuliani, M Oberto, L Occhi, C Rossi, I Rovelli, F Signorile, T Todros.

824 *Kenya:* W Stones and M Carvalho (Co- Principal Investigators), J Kizidio, R Ochieng, J
825 Shah, , S Vinayak, N Musee (until June 2011), C Kisiang'ani (until July 2011), D
826 Muninzwa (from August 2011).

827 *Oman:* YA Jaffer (Principal Investigator), J Al-Abri, J Al-Abduwani, FM Al-Habsi, H Al-
828 Lawatiya, B Al-Rashidiya, WKS Al-Zadjali, FR Juangco, M Venkataraman, H Al-Jabri
829 (until October 2010), D Yellappan (from November 2010).

830 *UK:* S Kennedy (Principal Investigator), L Cheikh Ismail, AT Papageorghiou, F
831 Roseman, A Lambert, EO Ohuma, S Lloyd, R Napolitano (from July 2011), C Ioannou
832 (until February 2012), I Sarris (until June 2010).

833 *USA:* MG Gravett (Principal Investigator), C Batiuk, M Batra, S Bornemeier, M Dighe, K
834 Oas, W Paulsene, D Wilson, IO Frederick, HF Andersen, SE Abbott, AA Carter, H
835 Algren, DA Rocco, TK Sorensen, D Enquobahrie, S Waller (until June 2011).

836

Table 1A: Smoothed centiles for fetal head circumference velocity increment (mm/week) according to gestational age

Gestational age (weeks)	FHC						
	C3	C5	C10	C50	C90	C95	C97
16	10.6	10.8	11.1	12.2	26.1	32.4	35.2
17	10.5	10.7	11.1	12.2	26.0	32.3	35.2
18	10.4	10.6	11.0	12.2	25.8	32.2	35.1
19	10.2	10.5	10.8	12.1	25.5	32.0	34.8
20	10.0	10.3	10.7	12.0	25.1	31.7	34.5
21	9.8	10.1	10.5	11.8	24.7	31.3	34.1
22	9.5	9.8	10.2	11.6	24.2	30.8	33.5
23	9.2	9.5	9.9	11.4	23.6	30.2	32.9
24	8.9	9.2	9.6	11.2	22.9	29.5	32.1
25	8.5	8.8	9.3	10.9	22.1	28.7	31.2
26	8.1	8.4	8.9	10.5	21.2	27.8	30.2
27	7.6	7.9	8.4	10.1	20.3	26.7	29.1
28	7.1	7.4	7.9	9.7	19.2	25.6	27.9
29	6.6	6.9	7.4	9.2	18.0	24.3	26.5
30	5.9	6.3	6.8	8.7	16.7	23.0	25.0
31	5.3	5.7	6.2	8.1	15.3	21.5	23.4
32	4.6	5.0	5.5	7.5	13.8	19.8	21.6
33	3.9	4.2	4.8	6.8	12.2	18.1	19.7
34	3.1	3.4	4.0	6.1	10.5	16.2	17.6
35	2.2	2.6	3.2	5.3	8.7	14.1	15.4

36	1.3	1.7	2.3	4.5	6.7	12.0	13.0
37	0.4	0.8	1.4	3.7	4.6	9.7	10.5
38	-0.6	-0.2	0.4	2.7	2.5	7.2	7.9

Journal Pre-proof

Table 1B: Smoothed centiles for fetal biparietal diameter velocity increment (mm/week)

according to gestational age

Gestational age (weeks)	BPD						
	C3	C5	C10	C50	C90	C95	C97
16	2.4	2.5	2.6	3.2	3.7	3.9	4.0
17	2.4	2.5	2.7	3.2	3.8	3.9	4.0
18	2.4	2.5	2.7	3.2	3.8	3.9	4.0
19	2.4	2.5	2.7	3.2	3.8	4.0	4.1
20	2.4	2.5	2.7	3.2	3.8	4.0	4.1
21	2.4	2.5	2.7	3.2	3.8	3.9	4.1
22	2.4	2.5	2.7	3.2	3.8	3.9	4.0
23	2.3	2.5	2.6	3.2	3.7	3.9	4.0
24	2.3	2.4	2.6	3.1	3.7	3.9	4.0
25	2.2	2.3	2.5	3.1	3.6	3.8	3.9
26	2.2	2.3	2.4	3.0	3.6	3.7	3.8
27	2.1	2.2	2.3	2.9	3.5	3.6	3.8
28	2.0	2.1	2.2	2.8	3.4	3.5	3.7
29	1.8	1.9	2.1	2.7	3.3	3.4	3.5
30	1.7	1.8	2.0	2.6	3.1	3.3	3.4
31	1.6	1.7	1.8	2.4	3.0	3.2	3.3
32	1.4	1.5	1.7	2.3	2.8	3.0	3.1
33	1.2	1.3	1.5	2.1	2.7	2.8	3.0
34	1.0	1.1	1.3	1.9	2.5	2.7	2.8
35	0.8	0.9	1.1	1.7	2.3	2.4	2.6
36	0.6	0.7	0.9	1.5	2.1	2.2	2.3
37	0.3	0.4	0.6	1.2	1.8	2.0	2.1
38	0.1	0.2	0.4	1.0	1.6	1.7	1.8

Table 1C: Smoothed centiles for fetal occipito-parietal diameter velocity increment (mm/week) according to gestational age

Gestational age (weeks)	OFD						
	C3	C5	C10	C50	C90	C95	C97
16	3.9	4.0	4.1	4.5	4.9	5.0	5.1
17	3.8	3.9	4.0	4.5	4.9	5.0	5.1
18	3.7	3.8	3.9	4.4	4.9	5.0	5.1
19	3.6	3.7	3.9	4.4	4.9	5.0	5.1
20	3.5	3.6	3.8	4.3	4.9	5.0	5.1
21	3.4	3.5	3.6	4.2	4.8	5.0	5.1
22	3.2	3.3	3.5	4.1	4.8	4.9	5.0
23	3.1	3.2	3.4	4.0	4.7	4.9	5.0
24	2.9	3.0	3.2	3.9	4.6	4.8	4.9
25	2.7	2.9	3.1	3.8	4.5	4.7	4.9
26	2.5	2.7	2.9	3.7	4.4	4.6	4.8
27	2.3	2.5	2.7	3.5	4.3	4.5	4.7
28	2.1	2.3	2.5	3.3	4.2	4.4	4.6
29	1.9	2.0	2.3	3.2	4.0	4.3	4.4
30	1.6	1.8	2.1	3.0	3.9	4.1	4.3
31	1.4	1.6	1.8	2.8	3.7	4.0	4.1
32	1.1	1.3	1.6	2.5	3.5	3.8	4.0
33	0.8	1.0	1.3	2.3	3.3	3.6	3.8
34	0.5	0.7	1.0	2.1	3.1	3.4	3.6
35	0.2	0.4	0.7	1.8	2.9	3.2	3.4
36	-0.1	0.1	0.4	1.5	2.6	2.9	3.1
37	-0.5	-0.3	0.1	1.2	2.4	2.7	2.9
38	-0.8	-0.6	-0.3	0.9	2.1	2.4	2.6

Table 1D: Smoothed centiles for fetal length velocity increment (mm/week) according to gestational age

Gestational age (weeks)	FL						
	C3	C5	C10	C50	C90	C95	C97
16	2.7	2.8	2.9	3.2	3.6	3.7	3.7
17	2.6	2.7	2.8	3.1	3.5	3.6	3.6
18	2.5	2.6	2.7	3.0	3.4	3.5	3.5
19	2.4	2.5	2.6	2.9	3.3	3.4	3.4
20	2.3	2.4	2.5	2.8	3.2	3.3	3.3
21	2.2	2.3	2.4	2.7	3.1	3.2	3.3
22	2.1	2.2	2.3	2.6	3.0	3.1	3.2
23	2.0	2.1	2.2	2.6	2.9	3.0	3.1
24	1.9	2.0	2.1	2.5	2.9	3.0	3.0
25	1.8	1.9	2.0	2.4	2.8	2.9	3.0
26	1.7	1.8	1.9	2.3	2.7	2.9	2.9
27	1.7	1.7	1.9	2.3	2.7	2.8	2.9
28	1.6	1.6	1.8	2.2	2.6	2.7	2.8
29	1.5	1.6	1.7	2.1	2.6	2.7	2.8
30	1.4	1.5	1.6	2.0	2.5	2.6	2.7
31	1.3	1.4	1.5	2.0	2.4	2.6	2.6
32	1.2	1.3	1.4	1.9	2.4	2.5	2.6
33	1.1	1.2	1.3	1.8	2.3	2.5	2.5
34	1.0	1.1	1.3	1.8	2.3	2.4	2.5
35	0.9	1.0	1.2	1.7	2.2	2.3	2.4
36	0.8	0.9	1.1	1.6	2.1	2.3	2.4
37	0.7	0.8	1.0	1.5	2.1	2.2	2.3
38	0.6	0.7	0.9	1.4	2.0	2.2	2.3

Table 1E: Smoothed centiles for abdominal circumference velocity increment (mm/week)

according to gestational age

Gestational age (weeks)	AC						
	C3	C5	C10	C50	C90	C95	C97
16	9.4	9.7	10.1	11.8	13.4	13.9	14.2
17	9.1	9.5	9.9	11.6	13.3	13.8	14.1
18	8.9	9.2	9.7	11.5	13.2	13.7	14.0
19	8.7	9.1	9.6	11.3	13.1	13.6	13.9
20	8.5	8.9	9.4	11.2	13.0	13.5	13.9
21	8.3	8.7	9.2	11.1	12.9	13.5	13.8
22	8.1	8.5	9.0	11.0	12.9	13.5	13.8
23	7.9	8.3	8.9	10.9	12.9	13.4	13.8
24	7.7	8.1	8.7	10.8	12.8	13.4	13.8
25	7.5	7.9	8.5	10.7	12.8	13.4	13.8
26	7.3	7.7	8.3	10.6	12.8	13.5	13.9
27	7.0	7.5	8.1	10.5	12.8	13.5	13.9
28	6.8	7.2	7.9	10.4	12.8	13.5	14.0
29	6.5	7.0	7.7	10.3	12.8	13.6	14.0
30	6.3	6.8	7.5	10.2	12.8	13.6	14.1
31	6.0	6.5	7.3	10.1	12.9	13.7	14.2
32	5.7	6.2	7.0	10.0	12.9	13.7	14.3
33	5.4	5.9	6.8	9.9	12.9	13.8	14.4
34	5.0	5.6	6.5	9.7	13.0	13.9	14.5
35	4.7	5.3	6.3	9.6	13.0	14.0	14.6
36	4.3	5.0	6.0	9.5	13.0	14.1	14.7
37	3.9	4.6	5.7	9.4	13.1	14.2	14.8
38	3.5	4.2	5.3	9.2	13.2	14.3	15.0

Figure legends

Figure 1: Increments in fetal head circumference (FHC), abdominal circumference (AC), and femur length (FL) (mm/week) according to gestational age (weeks) for all of the sites combined. The fitted 3rd, 50th and 97th centiles are superimposed.




Figure 2: Median velocity increments in fetal head circumference (FHC) (green), abdominal circumference (AC) (red), and femur length (FL) (blue) according to gestational age expressed as a percentage of the attained fetal size at 40 weeks' gestation according to the published international INTERGROWTH-21st Fetal (Distance) Growth Standards.¹

Figure 3: Screenshots of the fetal velocity app showing four example plots of longitudinal fetal growth evaluation based on observed and predicted measurements for a fetus representing: Figure 3A – normal fetus based on head circumference; Figure 3B – possible microcephaly based on head circumference; Figure 3C – a fetus within 2 standard deviations; Figure 3D – possible case of macrosomia based on abdominal circumference. All measurements are compared to the published international INTERGROWTH-21st Fetal (Distance) Growth Standards.¹

Supplementary Figure 1: Increments in biparietal diameter (BPD) and occipito-frontal diameter (OFD) (mm/week) according to gestational age (weeks) for all of the sites combined. The fitted 3rd, 50th and 97th centiles are superimposed.

Supplementary Figure 2: Median velocity increments in biparietal diameter (BPD) (green) and occipito-frontal diameter (OFD) (red) according to gestational age expressed as a percentage of the attained fetal size at 40 weeks' gestation according to the published international INTERGROWTH-21st Fetal (Distance) Growth Standards.¹

1. PAPAGEORGHIOU AT, OHUMA EO, ALTMAN DG, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. *Lancet* 2014;384:869-79.






Figure 3: Screenshots of the fetal velocity app showing four example plots of longitudinal fetal growth evaluation based on observed and predicted measurements for a fetus representing: Figure 3A – normal fetus based on head circumference; Figure 3B – possible microcephaly based on head circumference; Figure 3C – a fetus within 2 standard deviations based on head circumference; Figure 3D – possible case of macrosomia based on abdominal circumference. All measurements are in reference to the international fetal growth standards of the INTERGROWTH-21st Project.

Figure 3A

Longitudinal Fetal Growth Evaluation




Figure 3B

Longitudinal Fetal Growth Evaluation




Figure 3C

Longitudinal Fetal Growth Evaluation






Figure 3D

Longitudinal Fetal Growth Evaluation





STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 18.5.20 Manuscript # (if available): _____

Manuscript title: Fetal Growth Velocity Standards from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project

Corresponding author: Eric Ohuma

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable.

Typed or CLEARLY Printed Name:

Signature:

Yasmin Ahmed Jaffer

Typed or CLEARLY Printed Name:

Signature:

Typed or CLEARLY Printed Name:

Signature: